Medical research is the engine that drives innovation in heart rhythm care. As the field continues to advance and grow in complexity, the Heart Rhythm Society is committed to supporting  you and your colleagues who conduct high-quality groundbreaking research by fostering meaningful collaboration, exchange of insights and ideas, providing career development opportunities, and cultivating connections within the heart rhythm research community.

Asian And Caucasian Female Doctors Talking In Medical Research Center And Using Desktop Computer To Analyze MRI Scans Of Brain. Surgeon And Neuroscientist Discussing Solutions For Treating Alzheimer's
Cropped RN Logo

HRS Research Network

The HRS Research Network is a dedicated platform that aims to serve as a central convener, bringing together the multidisciplinary heart rhythm research community dedicated to improving the lives of patients with heart rhythm disorders through groundbreaking research discoveries.

Learn More

EPRFS Announcement SM

HRS Research Fellowship Scholarships

A post-doctoral research fellowship scholarships in cardiac electrophysiology, aiming to encouraging and supporting the research training of MDs, DOs, and PhDs in cardiac electrophysiology, focused on basic and clinical research.

Learn More

Research Flasks 1200 x 800

Letters of Endorsement for Research Studies Request

HRS offers its members letters of endorsement for basic, translational, and clinical research studies that advance the understanding and treatment of cardiac arrhythmias.

Learn More

capitol 2 1200x800

Research Advocacy

For more than 75 years, sustained federal investment has fueled life-saving discoveries that have transformed the diagnosis, treatment, and prevention of arrhythmias.  Today, the landscape of medical research faces growing uncertainty.  Heart Rhythm Advocates,  the advocacy voice of HRS,  focuses on raising awareness among policymakers and the public about the critical role of medical research & innovation in heart rhythm care.

Learn More

Doctor Working on Laptop

Resources

HRS offers a collection of resources available using the below search engine.

Search & Filter

Date Range

HRS Endorsed

Audience

Topic

Resource Type

Device Type

fallback image

Clinical Trials

ClinicalTrials.gov

ClinicalTrials.gov is a comprehensive resource for researchers focused on heart rhythm disorders, offering extensive data on ongoing and completed trials in arrhythmia and related conditions.

February 26, 2025

fallback image

Clinical Trials

The ARTESiA Trial

Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major…

November 12, 2023

fallback image

Clinical Trials

The EAST-AFNET 4 Trial

Early rhythm control therapy led to a significant reduction in adverse cardiovascular outcomes when compared to the usual care strategy.

August 29, 2020

fallback image

Clinical Trials

The CABANA Trial

Catheter ablation was not significantly more effective than drug therapy at preventing death, disabling stroke, serious bleeding, or cardiac arrest.

March 15, 2019

fallback image

Clinical Trials

The CRYSTAL AF Trial

ECG monitoring with an ICM was superior to conventional follow-up for detecting atrial fibrillation after stroke without a known cause.

June 26, 2014

fallback image

Clinical Trials

The ENGAGE AF-TIMI Trial

Edoxaban, an oral, reversible, direct factor Xa inhibitor, was noninferior to warfarin with respect to the prevention of stroke or systemic embolism and was associated…

November 28, 2013

fallback image

Clinical Trials

The BLOCK-HF Trial

Biventricular pacing was superior to conventional RV pacing in patients with AV block and LV systolic dysfunction with NYHA class I, II, or III heart…

April 25, 2013

fallback image

Clinical Trials

The ARISTOTLE Trial

In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.

September 15, 2011

fallback image

Clinical Trials

The ROCKET AF Trial

In patients with atrial fibrillation, rivaroxaban (factor Xa inhibition) was noninferior to warfarin (vitamin K antagonists) for the prevention of stroke or systemic embolism.

September 8, 2011

fallback image

Clinical Trials

The AVERROES Trial

In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing…

March 3, 2011